BackAridis Pharmaceuticals Overview

Aridis Pharmaceuticals Selling, General & Admin

Explore Aridis Pharmaceuticals's selling, general & admin with historical charts and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$1.11M
34.38% YoY

As of Sep 30, 2023

Annual SG&A Expenses (TTM)

$5.86M
21.71% YoY

Trailing 12 months ending Sep 30, 2023

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Aridis Pharmaceuticals (ARDS) FAQ

Stockcircle tracks selling, general & admin for Aridis Pharmaceuticals (ARDS), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Aridis Pharmaceuticals's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main ARDS overview so you can move from this figure to the surrounding analysis quickly.